Jakafi (Ruxolitinib Phosphate) Patent Expiration, LOE Window & CMS Spending

Jakafi (Ruxolitinib Phosphate) by Incyte: FDA Orange Book core substance LOE 2028-12-12 (last listed 2029-03-22), 0 AB generics, $2.24B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIncyte
FDA Application & PathwayN202192 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-12-12
Last Listed Patent or Exclusivity Date2029-03-22
Orange Book Patents (*PED Extensions)16 patents (8 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.24B
2024 Medicare Part D Spend$2.08B
2024 Medicaid Spend$161.4M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 20.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.